Jan Moritz Middeke

Jan Moritz Middeke

Auto-generated profile, based on publicly available information

Jan Moritz Middeke

Department of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in Cytotherapy
Verified
Journal Article
Closed access
ATAnke Theil
Anke Theil
STSebastian Tuve
Sebastian Tuve
UOUta Oelschlägel
Uta Oelschlägel
AMAnja Maiwald
Anja Maiwald
DDDiana Döhler
Diana Döhler
MBMartin Bornhäuser
Martin Bornhäuser

8 September 2021 in Leukemia
Verified
Journal Article
Open access
PDF file
JEJan-Niklas Eckardt
Jan-Niklas Eckardt
JMJan Moritz Middeke
Jan Moritz Middeke
SRSebastian Riechert
Sebastian Riechert
TSTim Schmittmann
Tim Schmittmann
ASAnas Shekh Sulaiman
Anas Shekh Sulaiman
MBMartin Bornhäuser
Martin Bornhäuser
The evaluation of bone marrow morphology by experienced hematopathologists is essential in the diagnosis of acute myeloid leukemia (AML); however, it suffers from a lack of standardization and inter-observer variability. Deep learning (DL) can process medical image data and provides data-driven class predictions. Here, we apply a multi-step DL approach to automatically segment cells from bone marrow images, distinguish between AML samples and healthy controls with an area under the receiver operating characteristic (AUROC) of 0.9699, and predict the mutation status of Nucleophosmin 1 (NPM1)—one of the most common mutations in AML—with an AUROC of 0.92 using only image data from bone marrow smears. Utilizing occlusion sensitivity maps, we observed so far unreported morphologic cell features such as a pattern of condensed chromatin and perinuclear lightening zones in myeloblasts of NPM1-mutated AML and prominent nucleoli in wild-type NPM1 AML enabling the DL model to provide accurate class predictions.

15 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JEJan-Niklas Eckardt
Jan-Niklas Eckardt
KWKarsten Wendt
Karsten Wendt
MBMartin Bornhäuser
Martin Bornhäuser
JMJan Moritz Middeke
Jan Moritz Middeke
Precision oncology is grounded in the increasing understanding of genetic and molecular mechanisms that underly malignant disease and offer different treatment pathways for the individual patient. The growing complexity of medical data has led to the implementation of machine learning techniques that are vastly applied for risk assessment and outcome prediction using either supervised or unsupervised learning. Still largely overlooked is reinforcement learning (RL) that addresses sequential tasks by exploring the underlying dynamics of an environment and shaping it by taking actions in order to maximize cumulative rewards over time, thereby achieving optimal long-term outcomes. Recent breakthroughs in RL demonstrated remarkable results in gameplay and autonomous driving, often achieving human-like or even superhuman performance. While this type of machine learning holds the potential to become a helpful decision support tool, it comes with a set of distinctive challenges that need to be addressed to ensure applicability, validity and safety. In this review, we highlight recent advances of RL focusing on studies in oncology and point out current challenges and pitfalls that need to be accounted for in future studies in order to successfully develop RL-based decision support systems for precision oncology.

13 January 2016 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
JMJan M. Middeke
Jan M. Middeke
SHSylvia Herold
Sylvia Herold
ERElke Rücker‐Braun
Elke Rücker‐Braun
WBWolfgang E. Berdel
Wolfgang E. Berdel
MSMatthias Stelljes
Matthias Stelljes
T(the Study Alliance Leukaemia (SAL)
the Study Alliance Leukaemia (SAL)

15 January 2016 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
FSF Stölzel
F Stölzel
BMB Mohr
B Mohr
MKM Kramer
M Kramer
UOU Oelschlägel
U Oelschlägel
TBT Bochtler
T Bochtler
GEG Ehninger
G Ehninger
A complex aberrant karyotype consisting of multiple unrelated cytogenetic abnormalities is associated with poor prognosis in patients with acute myeloid leukemia (AML). The European Leukemia Net classification and the UK Medical Research Council recommendation provide prognostic categories that differ in the definition of unbalanced aberrations as well as the number of single aberrations. The aim of this study on 3526 AML patients was to redefine and validate a cutoff for karyotype complexity in AML with regard to adverse prognosis. Our study demonstrated that (1) patients with a pure hyperdiploid karyotype have an adverse risk irrespective of the number of chromosomal gains, (2) patients with translocation t(9;11)(p21∼22;q23) have an intermediate risk independent of the number of additional aberrations, (3) patients with ⩾4 abnormalities have an adverse risk per se and (4) patients with three aberrations in the absence of abnormalities of strong influence (hyperdiploid karyotype, t(9;11)(p21∼22;q23), CBF-AML, unique adverse-risk aberrations) have borderline intermediate/adverse risk with a reduced overall survival compared with patients with a normal karyotype.

1 June 2018 in Journal of Autoimmunity
Verified
Journal Article
Closed access
SKStefanie Koristka
Stefanie Koristka
AKAlexandra Kegler
Alexandra Kegler
RBRalf Konrad Dr. Bergmann
Ralf Konrad Dr. Bergmann
CAClaudia Arndt
Claudia Arndt
AFAnja Feldmann
Anja Feldmann
MBMichael Bachmann
Michael Bachmann